Condition
Epileptic Syndromes
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results33% success
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Terminated2
Recruiting1
Unknown1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04912856Phase 3Terminated
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
NCT04639310Phase 3Terminated
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
NCT06223334RecruitingPrimary
Epileptic Syndromes in Infants and Early Childhood
NCT06222840CompletedPrimary
Electro-clinical Features and Functional Connectivity Analysis in SYN1 Gene Mutation-related Epilepsy
NCT04048213Unknown
The Becoming of Children With Doose Syndrome
Showing all 5 trials